Tagged with Alzheimer's

Europe The European Brain Council (EBC) is a key player in advancing brain health research and policy across Europe, bringing together diverse voices to address the pressing issues of neurological and mental health. As Frédéric Destrebecq, the EBC’s Executive Director, explains, “We must restore the trust between science and society for…

United Kingdom Fiona Carragher, Chief Policy and Research Officer at Alzheimer’s Society, delves into the organization’s mission to transform dementia care through innovation, advocacy, and global collaboration. Carragher addresses critical challenges, including delayed diagnoses, gaps in social care, and the need for inclusivity in clinical trials, while emphasizing the role of technology…

Europe The Women’s Brain Foundation, formerly the Women’s Brain Project, has evolved into a fully-fledged foundation dedicated to advancing research in gender precision medicine with a strong focus on brain health. CEO pro-bono Dr Antonella Santuccione Chadha comments on the organisation’s newly extended global reach, progress in understanding the link between…

Global In conversation at Clinical Trials on Alzheimer’s Disease (CTAD) 2024 in Madrid, Roche Diagnostics’ Margherita Carboni discusses the potential of blood-based biomarkers to transform Alzheimer’s diagnostics, offering a faster and less invasive alternative to traditional methods. She highlights Roche’s commitment to ensuring diversity in clinical trials, a crucial step in…

Global Almost 2,500 attendees flocked to Madrid last week for the 2024 edition of Clinical Trials on Alzheimer’s Disease (CTAD). The first European edition of the conference since 2018 was punctuated by a mood of excitement, with Leqembi (lecanemab) – the second drug that targets Alzheimer’s disease progression by reducing amyloid…

Hong Kong Professor at the Chinese University of Hong Kong since 1993 and pioneer in studying the causes of stroke in China, Lawrence Wong comments on neurology advancements over the past 30 years; the increasing number of Alzheimer’s cases amongst Asian populations, and the need to go from a symptomatic approach to…

Hong Kong Andrea Chang, general manager of Eisai Hong Kong explains the importance of the firm’s FDA-approved Biogen-partnered Alzheimer’s disease (AD) product, particularly in Hong Kong where some 20 percent of the population is aged 65 or older. In addition, she outlines Eisai’s oncology and neurology-focused portfolio; the potential provided by Hong…

USA Eli Lilly has turned its numbers around and become the world’s most valuable pharma company, thanks to its type 2 diabetes and off-label use obesity drug tirzeptide, which generated no less than USD 1.4 billion in its first full quarter on the market. As the US firm prepares to launch…

Global Eli Lilly recently revealed more than promising clinical trial results for its Alzheimer’s candidate, donanemab, showing that the drug slows Alzheimer’s by as much as 60 percent in mild cases. While safety concerns about the drug remain, Lilly is hoping for an FDA approval by the end of the year.…

Canada Drs Neil Cashman and Larry Altstiel of ProMIS Neurosciences weigh in on recent progress towards an effective therapy for Alzheimer’s disease, potentially representing a break from three decades of scientific stagnation.   Are we there yet with Alzheimer’s immunotherapies? No. But we have a map, and it’s a good one.…

Spain The Pasqual Maragall Foundation is a Spanish non-profit research organization dedicated to the research of Alzheimer’s disease. Its director, Arcadi Navarro, takes from his decades-long scientific career in genomics to explain the main theories and discoveries shaping the push to find a next-generation treatment, or even possible cure, for Alzheimer’s.…

Spain Biogen’s managing director for Spain, Sergio Teixeira, reflects on the company’s key role in transforming multiple sclerosis and spinal muscular atrophy as examples of the American biotech giant commitment to transforming neuroscience. The Portuguese executive also analyzes what he describes as a “positive” momentum for biosimilars in Spain amongst his…